Eupraxia Pharmaceuticals (EPRX) FCF Payout Ratio Growth (1y) (2024 - 2025)
Eupraxia Pharmaceuticals (EPRX) FCF Payout Ratio Growth (1y) (2024 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.68 Bn | 467.89 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.24 Bn | 114.99 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.33 Bn | 3.31 Bn | 0.27% |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.75 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.59 Bn | 34.58 Bn | 959.66 Mn | - |
| 10 | Eupraxia Pharmaceuticals | 346.80 Mn | 346.80 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1,177.62% |
| Jun 30, 2025 | -42.41% |
| Mar 31, 2025 | 19.66% |
| Sep 30, 2024 | 184.52% |
| Jun 30, 2024 | 1,511.77% |
| Mar 31, 2024 | -91.75% |